durvalumab,tremelimumab
astrazeneca
[]
#gi23 infinity : 3 mo of dual cpi resulted in 60% pcr in dmmr gastric/gejxn adeno. the trial is amended to exclude ct4 and allows non-operative management. 
Med Onc, Director GI Oncology @ProvHealth @ChilesResearch, Co-chair SWOG Rectal-Anal Cmmtee, NCI GSC Member, #colorectalcancer #NETs. Cycling & ski enthusiast!